⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14870287 | 0.63 | NOS3 (0.33) | — | |
| SCHEMBL20403358 | 0.54 | — | — | |
| SCHEMBL1767692 | 0.51 | — | — | |
| SCHEMBL1767793 | 0.46 | — | — | |
| SCHEMBL8465809 | 0.38 | CASP1 (0.50) | — | |
| SCHEMBL25853 | 0.38 | — | — | |
| SCHEMBL8356506 | 0.38 | CASP1 (0.50) | — | |
| SCHEMBL10414868 | 0.38 | NQO1 (0.50) | — | |
| SCHEMBL175612 | 0.38 | CASP1 (0.50) | — | |
| SCHEMBL2362493 | 0.38 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10201511-B2 | Compositions and methods for treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-1611111-B1 | PROCESS FOR RESOLVING 2,4-DIAMINO-3,6-DIHYDRO-1,3,5-TRIAZINES, USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULIN RESISTANCE SYNDROME | MERCK PATENT GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1611111-A2 | PROCESS FOR RESOLVING 2,4-DIAMINO-3,6-DIHYDRO-1,3,5-TRIAZINES, USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULIN RESISTANCE SYNDROME | MERCK PATENT GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089917-A3 | PROCESS FOR RESOLVING 2,4-DIAMINO-3,6-DIHYDRO-1,3,5-TRIAZINES, USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULIN RESISTANCE SYNDROME | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004089917-A2 | PROCESS FOR RESOLVING 2,4-DIAMINO-3,6-DIHYDRO-1,3,5-TRIAZINES, USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULIN RESISTANCE SYNDROME | MERCK PATENT GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |